Literature DB >> 19582387

Caldesmon expression is decreased in women with anterior vaginal wall prolapse: a pilot study.

Peter Takacs1, Marc Gualtieri, Mehdi Nassiri, Keith Candiotti, Alessia Fornoni, Carlos A Medina.   

Abstract

INTRODUCTION AND HYPOTHESIS: The purpose of this study is to compare vaginal caldesmon expression in women with and without anterior vaginal wall prolapse.
METHODS: Vaginal tissues were sampled in women with (n = 11) or without (n = 11) vaginal wall prolapse. Caldesmon messenger RNA (mRNA) expression was assessed by quantitative real-time polymerase chain reaction. Immunohistochemistry and digital image analysis were used to determine caldesmon protein expression in the histologic sections.
RESULTS: There were no significant differences in demographic data between the two groups. Caldesmon mRNA expression was significantly decreased in the vaginal tissue from women with anterior vaginal wall prolapse compared to women without prolapse [(caldesmon mean +/- SD mRNA expression in relative units) 0.03 +/- 0.03 vs 0.17 +/- 0.17, P = 0.02]. The fractional area of nonvascular caldesmon staining in the vagina of women with anterior vaginal wall prolapse was significantly decreased compared to women without prolapse [mean +/- SD (0.09 +/- 0.04 vs 0.16 +/- 0.09, P = 0.03)].
CONCLUSIONS: Vaginal caldesmon expression is significantly decreased in women with anterior vaginal wall prolapse compared to normal subjects.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19582387     DOI: 10.1007/s00192-009-0876-z

Source DB:  PubMed          Journal:  Int Urogynecol J Pelvic Floor Dysfunct


  17 in total

Review 1.  Actin and the smooth muscle regulatory proteins: a structural perspective.

Authors:  J L Hodgkinson
Journal:  J Muscle Res Cell Motil       Date:  2000-02       Impact factor: 2.698

2.  Morphometric properties of the posterior vaginal wall in women with pelvic organ prolapse.

Authors:  Muriel K Boreham; Clifford Y Wai; Rodney T Miller; Joseph I Schaffer; R Ann Word
Journal:  Am J Obstet Gynecol       Date:  2002-12       Impact factor: 8.661

3.  Caldesmon mutant defective in Ca(2+)-calmodulin binding interferes with assembly of stress fibers and affects cell morphology, growth and motility.

Authors:  Yan Li; Jenny L C Lin; Rebecca S Reiter; Karla Daniels; David R Soll; Jim J C Lin
Journal:  J Cell Sci       Date:  2004-06-29       Impact factor: 5.285

4.  The standardization of terminology of female pelvic organ prolapse and pelvic floor dysfunction.

Authors:  R C Bump; A Mattiasson; K Bø; L P Brubaker; J O DeLancey; P Klarskov; B L Shull; A R Smith
Journal:  Am J Obstet Gynecol       Date:  1996-07       Impact factor: 8.661

5.  Epidemiology of surgically managed pelvic organ prolapse and urinary incontinence.

Authors:  A L Olsen; V J Smith; J O Bergstrom; J C Colling; A L Clark
Journal:  Obstet Gynecol       Date:  1997-04       Impact factor: 7.661

6.  Over expression of smooth muscle thin filament associated proteins in the bladder wall of diabetics.

Authors:  Anita S Mannikarottu; Arun K Changolkar; Michael E Disanto; Alan J Wein; Samuel Chacko
Journal:  J Urol       Date:  2005-07       Impact factor: 7.450

7.  Regulation of vascular smooth muscle tone by caldesmon.

Authors:  H Katsuyama; C L Wang; K G Morgan
Journal:  J Biol Chem       Date:  1992-07-25       Impact factor: 5.157

8.  The role of partial denervation of the pelvic floor in the aetiology of genitourinary prolapse and stress incontinence of urine. A neurophysiological study.

Authors:  A R Smith; G L Hosker; D W Warrell
Journal:  Br J Obstet Gynaecol       Date:  1989-01

9.  Smooth muscle fraction of the round ligament in women with pelvic organ prolapse: a computer-based morphometric analysis.

Authors:  Ozlem Ozdegirmenci; Yildirim Karslioglu; Suat Dede; Sinan Karadeniz; Ali Haberal; Omer Gunhan; Bulent Celasun
Journal:  Int Urogynecol J Pelvic Floor Dysfunct       Date:  2004-09-08

10.  Role of caldesmon in the Ca2+ regulation of smooth muscle thin filaments: evidence for a cooperative switching mechanism.

Authors:  Saira Ansari; Mustapha Alahyan; Steven B Marston; Mohammed El-Mezgueldi
Journal:  J Biol Chem       Date:  2007-10-12       Impact factor: 5.157

View more
  7 in total

1.  TGF-beta 1 is a potential regulator of vaginal tropoelastin production.

Authors:  Peter Takacs; Yanping Zhang; Sujata Yavagal; Keith Candiotti; Nahida Chakhtoura; Carlos A Medina
Journal:  Int Urogynecol J       Date:  2011-11-09       Impact factor: 2.894

2.  Effect of estrogen on molecular and functional characteristics of the rodent vaginal muscularis.

Authors:  Maureen E Basha; Shaohua Chang; Lara J Burrows; Jenny Lassmann; Alan J Wein; Robert S Moreland; Samuel Chacko
Journal:  J Sex Med       Date:  2013-02-25       Impact factor: 3.802

3.  Regional differences in rat vaginal smooth muscle contractility and morphology.

Authors:  Laura C Skoczylas; Zegbeh Jallah; Yoshio Sugino; Suzan E Stein; Andrew Feola; Naoki Yoshimura; Pamela Moalli
Journal:  Reprod Sci       Date:  2013-01-08       Impact factor: 3.060

4.  Contractile response of human anterior vaginal muscularis in women with and without pelvic organ prolapse.

Authors:  Gina M Northington; Maureen Basha; Lily A Arya; Alan J Wein; Samuel Chacko
Journal:  Reprod Sci       Date:  2010-12-30       Impact factor: 3.060

5.  The impact of prolapse mesh on vaginal smooth muscle structure and function.

Authors:  Z Jallah; R Liang; A Feola; W Barone; S Palcsey; S D Abramowitch; N Yoshimura; P Moalli
Journal:  BJOG       Date:  2015-08-20       Impact factor: 6.531

6.  A Non-Invasive Determination of LOXL1 and Fibulin-5 Levels in the Vaginal Secretions of Women with and Without Pelvic Organ Prolapse.

Authors:  Bobby Garcia; Afiba Arthur; Bansari Patel; Jenny Chang; Dongbao Chen; Felicia Lane
Journal:  J Med Res Surg       Date:  2021-04-12

Review 7.  The calpain system as a potential target for pelvic muscle reinforcement.

Authors:  Mariusz Blewniewski; Ewa Forma; Waldemar Różański; Magdalena Bryś
Journal:  Cent European J Urol       Date:  2011-09-06
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.